4/26
08:06 am
cgon
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 [Yahoo! Finance]
High
Report
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 [Yahoo! Finance]
4/26
08:00 am
cgon
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
High
Report
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
4/24
10:15 am
cgon
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 [Yahoo! Finance]
Low
Report
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 [Yahoo! Finance]
4/24
10:00 am
cgon
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
Low
Report
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
4/11
10:14 pm
cgon
20 Countries with the Most Domestically Listed Companies in the World [Yahoo! Finance]
Low
Report
20 Countries with the Most Domestically Listed Companies in the World [Yahoo! Finance]
4/11
04:57 am
cgon
PACS Group to raise $450 mln in US IPO at over $3 bln valuation [Reuters]
Medium
Report
PACS Group to raise $450 mln in US IPO at over $3 bln valuation [Reuters]
4/10
11:58 pm
cgon
UPDATE 1-PACS Group to raise $450 mln in US IPO at over $3 bln valuation [Yahoo! Finance]
Medium
Report
UPDATE 1-PACS Group to raise $450 mln in US IPO at over $3 bln valuation [Yahoo! Finance]
4/4
08:04 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
3/28
08:09 am
cgon
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting [Yahoo! Finance]
3/28
08:00 am
cgon
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
Medium
Report
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
3/19
04:07 pm
cgon
How to Find Up-and-Coming Stocks to Buy Right Now [Yahoo! Finance]
Low
Report
How to Find Up-and-Coming Stocks to Buy Right Now [Yahoo! Finance]
2/27
08:00 am
cgon
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
Low
Report
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
2/22
08:00 am
cgon
ORI Capital Raises $260 Million for Second Life Sciences Fund
Low
Report
ORI Capital Raises $260 Million for Second Life Sciences Fund
2/20
07:29 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $75.00 price target on the stock.
Medium
Report
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $75.00 price target on the stock.
2/20
07:17 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $42.00 price target on the stock.
Medium
Report
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $42.00 price target on the stock.
2/20
07:17 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $42.00 price target on the stock.
Medium
Report
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $42.00 price target on the stock.
2/20
07:17 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $55.00 price target on the stock.
Medium
Report
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $55.00 price target on the stock.
2/20
07:17 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $55.00 price target on the stock.
Medium
Report
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $55.00 price target on the stock.
2/14
07:10 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $75.00 price target on the stock.
Low
Report
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $75.00 price target on the stock.
1/30
07:00 am
cgon
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Neutral
Report
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares